- Home
- LAZ vs AXSM Comparison
LAZ vs AXSM Comparison
Compare LAZ & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LAZ
- AXSM
- Stock Information
- Founded
- LAZ 1848
- AXSM 2012
- Country
- LAZ United States
- AXSM United States
- Employees
- LAZ N/A
- AXSM N/A
- Industry
- LAZ Investment Managers
- AXSM Biotechnology: Pharmaceutical Preparations
- Sector
- LAZ Finance
- AXSM Health Care
- Exchange
- LAZ Nasdaq
- AXSM Nasdaq
- Market Cap
- LAZ 4.8B
- AXSM 4.2B
- IPO Year
- LAZ 2005
- AXSM 2015
- Fundamental
- Price
- LAZ $49.51
- AXSM $137.75
- Analyst Decision
- LAZ Hold
- AXSM Strong Buy
- Analyst Count
- LAZ 7
- AXSM 14
- Target Price
- LAZ $55.33
- AXSM $158.93
- AVG Volume (30 Days)
- LAZ 967.6K
- AXSM 1.1M
- Earning Date
- LAZ 01-30-2025
- AXSM 02-18-2025
- Dividend Yield
- LAZ 4.02%
- AXSM N/A
- EPS Growth
- LAZ N/A
- AXSM N/A
- EPS
- LAZ 2.68
- AXSM N/A
- Revenue
- LAZ $3,051,837,000.00
- AXSM $385,693,000.00
- Revenue This Year
- LAZ $4.69
- AXSM $45.18
- Revenue Next Year
- LAZ $10.74
- AXSM $65.22
- P/E Ratio
- LAZ $18.56
- AXSM N/A
- Revenue Growth
- LAZ 21.05
- AXSM 42.53
- 52 Week Low
- LAZ $35.56
- AXSM $64.11
- 52 Week High
- LAZ $61.14
- AXSM $139.13
- Technical
- Relative Strength Index (RSI)
- LAZ 39.01
- AXSM 74.55
- Support Level
- LAZ $51.27
- AXSM $124.04
- Resistance Level
- LAZ $55.58
- AXSM $130.52
- Average True Range (ATR)
- LAZ 1.67
- AXSM 5.78
- MACD
- LAZ -0.32
- AXSM 1.11
- Stochastic Oscillator
- LAZ 5.89
- AXSM 96.07
About LAZ Lazard Inc.
Lazard has a storied history that can be traced back to 1848. The company's revenue is nearly equally split between financial advisory, such as acquisition and restructuring advisory, and asset management. The company's asset management business is primarily equities (over 80% of assets under management), has an international focus, and is geared toward institutional clients. By geography, the company earns approximately 60% of revenue in the Americas, 35% in EMEA, and 5% in Asia-Pacific. Lazard has offices across more than 20 countries and over 3,000 employees.
About AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.